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Abstract
We previously showed intravaginal inoculation with SHIVsf162p3 results in transient viremia followed by undetectable
viremia in most macaques, and some displayed subsequent immunity to superinfection with pathogenic SIVmac251. Here
we compare early T cell activation, proliferation, and plasma cytokine/chemokine responses in macaques intravaginally
infected with either SHIVsf162p3 or SIVmac251 to determine whether distinct differences in host responses may be
associated with early viral containment. The data show SIVmac251 infection results in significantly higher levels of T cell
activation, proliferation, and a mixed cytokine/chemokine ‘‘storm’’ in plasma in primary infection, whereas infection with
SHIVsf162p3 resulted in significantly lower levels of T cell activation, proliferation, and better preservation of memory CD4+
T cells in early infection which immediately preceded control of viremia. These results support the hypothesis that early
systemic immune activation, T cell proliferation, and a more prominent and broader array of cytokine/chemokine responses
facilitate SIV replication, and may play a key role in persistence of infection, and the progression to AIDS. In contrast,
immune unresponsiveness may be associated with eventual clearance of virus, a concept that may have key significance for
therapy and vaccine design.
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Introduction
Rhesus macaques are the premier animal model for studying
the pathogenesis and immunology of HIV infection. However,
there are numerous simian immunodeficiency viruses (SIVs) and
chimeric simian/human immunodeficiency viruses (SHIVs), each
with different characteristics and pathogenicity. Most SHIVs are
easily transmissible and initially highly infectious, yet most SHIV-
infected macaques fail to maintain plasma viremia for more than a
few weeks/months, making these viruses less useful for pathogen-
esis or vaccine studies. For example, SHIVsf162P3 was originally
described as a pathogenic SHIV, and some rhesus macaques
clearly develop AIDS when infected with this virus [1], yet while
most SHIV-infected macaques have marked peak viremia, and
often similar to those infected with more pathogenic viruses, the
majority fail to sustain viremia, and most clear infection, at least to
undetectable levels in plasma within a few weeks of infection.
Although the reasons for these disparate outcomes are unknown,
few studies have directly compared the host responses in identical
cohorts of macaques inoculated with a pathogenic virus (SIV-
mac251) with those infected with a virus that results in early high
viremia, but is eventually cleared to undetectable levels in plasma,
such as SHIVsf162P3.
In macaques, SIVmac251 is among the most widely used virus
for examining the immunology and pathogenesis of HIV infection
in humans, largely due to its high infectivity, persistent and stable
post peak (set point) viremia, and high rate of progression to AIDS
within 1–3 years. In contrast, the majority of SHIVsf162P3-
infected macaques initially have high viremia, similar to animals
infected with SIVmac251, yet most have undetectable viremia
(,125 viral copies/ml) within 60–90 days of infection [2]. The
fact that animals are easily infected, support high peak viral
replication, and initially lose intestinal CD4+ T cells [3]
demonstrate these animals are not inherently resistant to infection,
and have ample viral target cells to support replication. Since most
SHIV-infected animals ‘‘clear’’ or control infection to undetect-
able levels, we hypothesized there would be detectable differences
in immune responses between macaques infected with SIV
mac251, which may yield correlates of a protective immune
response that prevents animals from progressing to AIDS.
Human immunodeficiency virus (HIV) infection in humans and
experimental SIV infection in rhesus macaques results in peak
viremia, marked non-specific immune activation, T cell prolifer-
ation, intestinal CD4+ T cell depletion, and in the chronic stage,
persistently high viremia with eventual progression to AIDS [4,5].
In contrast, natural primate hosts for SIV (such as African green
monkeys, sooty mangabeys, etc.) generally do not progress to
AIDS when infected with SIV, and maintain normal levels of
T-cell activation, proliferation and apoptosis during chronic
infection, despite persistently high levels of viral replication
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against HIV and SIV are sometimes predictive of disease outcome
[9,11,12], few correlates of immune protection or viral control
have been identified to date. Perhaps this is because investigators
have sought enhanced or more prominent immune responses
associated with control of viremia. It has long been known that
SIV and HIV selectively replicate in activated memory CD4+ T
cells. More recently, abundant evidence indicates increased
immune activation and T cell proliferation is a major correlate
of increased viral replication and progression to AIDS in HIV and
SIV infection [10,13]. Thus, we compared these parameters in
rhesus macaques inoculated with viruses that result in different
outcomes, now hypothesizing that increased immune activation
may actually be detrimental to the host, and that dampened
immune responses may be associated with the clearance of virus
from hosts infected with SHIVsf162p3. Examining potentially
divergent immune responses between pathogenic and nonpatho-
genic infection with closely related viruses may yield clues
regarding the pathogenesis of AIDS as well as the immune
mechanisms involved in control of viremia. Here we compared
levels of immune activation, cell proliferation, and cytokine/
chemokine production in macaques infected with SHIVsf162p3 to
those with SIVmac251.
Materials and Methods
Animals and virus infection
A total of thirty-six Indian-origin rhesus macaques (Macaca
mulatta), which were initially negative for HIV-2, SIV, type D
retrovirus, and STLV-1 infection were examined in this study. All
animals were housed at the Tulane National Primate Research
Center in accordance with the standards of the Association for
Assessment and Accreditation of Laboratory Animal Care
International. All studies were reviewed and approved by the
Tulane University Institutional Animal Care and Use Committee.
Of these, sixteen and fourteen SIV-negative animals were
intravaginally inoculated with SHIVsf162P3 and SIVmac251
respectively as previously described and blood from another 6
uninfected animals were added to controls [14]. Experimental
macaques were intramuscularly treated with Depo proveraH
(30 mg) 28–32 days prior to vaginal challenge with 300TCID50
of either virus which corresponded to 2.8610
7 RNA copies/ml of
SIVmac251 and 9.1610
7 RNA copies of SHIVsf162p3 per
inoculum.
Sample collection and flow cytometry
Fresh blood was collected in EDTA Vacutainer tubes. Plasma
was collected by centrifugation at 1000 g for 20 min at 4uC,
aliquoted, and stored at 270uC until analysis.
Directly conjugated anti-human antibodies were obtained from
BD Biosciences (San Jose, CA) unless stated otherwise. Peripheral
blood was stained using a whole blood lysis protocol as previously
described [14]. In brief, 100 ml whole blood was incubated with
monoclonal antibodies for 30 min at 4uC, followed by a 7-min lyse
with FACS lysing solution (Becton Dickinson, San Jose, Calif.).
Cells were then washed (4006g, 7 min) and resuspended in 2%
paraformaldehyde. Antibodies included anti-CD3 (clone SP34-2)-
PE-Cy7 or Pacific Blue; anti-CD4 (clone L200)-Amcyan; anti-
CD8 (3B5, Caltag)-PE-TxR or –Qdot 655; anti-HLA-DR (clone
Immu-357, Beckman Coulter)–ECD; anti-CD95 (clone DX2)-PE-
Cy5 and anti-CD28 (clone CD28.2, Biolegend)-Alexa 700. For
assessing proliferation, whole blood was surface stained, treated
with FACS lysing solution, washed, and intracellularly stained with
anti-Ki67 (Clone B56) as previously described [15]. Samples were
acquired on a FACSAria or LSR II (BD Biosciences) and data
analyzed using Flow Jo software (Tree Star, Inc., San Carlos, CA).
Viral quantification in plasma
Plasma viremia was quantified using a bDNA assay (Seimens
Diagnostics Inc.) as previously described [16]. The sensitivity of
detection was 125 viral RNA copies/ml plasma.
Detection of cytokines/chemokines in plasma by
multiplex microbead immunoassay
A multiplex biometric immunoassay, containing fluorescent
dyed microspheres conjugated with a monoclonal antibody
specific for the target protein was used for cytokine measurements
according to the manufacturer’s instructions (Bio-Plex Human
Cytokine Assay; Bio-Rad Inc., Hercules, CA, USA). 27 cytokines
were measured in the kit (171A11127-27 plex, Bio-Rad). Briefly,
50 ml diluted plasma (1:1) was incubated with antibody-coupled
beads. Complexes were washed, incubated with biotinylated
detection antibody, and then streptavidin-PE. A range of 1.95–
32,000 pg/ml of recombinant human cytokines was used to
establish standard curves and maximize sensitivity of the assay.
Cytokine levels were determined using a multiplex array reader
from Luminex
TM Instrumentation System (Bio-Plex Workstation
from Bio-Rad Laboratories). Analyte concentrations were calcu-
lated using software provided by the manufacturer (Bio-Plex
Manager Software).
Statistics
Graphical presentation and statistical analysis of the data were
performed using GraphPad Prism 4.0 (GraphPad Software,
SanDiego, CA). Comparisons between groups or between time
points were performed using a two-tailed unpaired and paired
t-test. P values,0.05 were considered statistically significant.
Results
Differential replication of SHIVsf162P3 and SIVmac251 in
acute infection of rhesus macaques
Here, we compared responses of macaques intravaginally
inoculated with either SHIVsf162P3 or SIVmac251. As shown
in Fig. 1, peak viral loads were slightly lower, and peak viremia
Figure 1. Plasma viremia in early SHIVsf162p3 (n=11; filled
circles) and SIVmac251 (n=16; open squares) infected rhesus
macaques. Means 6SEM are shown.
doi:10.1371/journal.pone.0017965.g001
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compared to SIVmac251, (Fig. 1). Mean peak viral loads ranged
from 1.5610
6 to 6.3610
6 copies/ml in SHIVsf162p3-infected
animals, and 5.1610
6 to 4.7610
7 copies/ml in SIVmac251-
infected macaques at 14 and 21 days postinfection respectively. By
28 days of infection however, viral loads in SHIVsf162P3 infected
animals were dramatically lower, and continually decreased to low
or undetectable levels by 70 days of infection. In contrast, viremia
remained high throughout infection in SIVmac251-infected
animals (Fig. 1).
Limited T-cell activation in early SHIV-infection
To characterize early host responses, HLA-DR expression was
examined on T cells to assess levels of activation after infection.
The representative gating strategy for HLA-DR+ T-cell is
shown in Figure 2A). Throughout acute infection, percentages
of activated (HLA-DR+) CD3+, CD4+ and CD8+ T cells in
SHIV162p3-infected animals were consistently lower in maca-
ques infected with SHIV than SIVmac251. Levels of T cell
activation were already significantly higher in SIVmac251-infected
macaques at 7 days (p,0.001 for CD3+;p ,0.001 for CD4+
and p,0.05 for CD8+ T cells) and 21 days post infection
(p,0.01 for CD3+;p ,0.05 for both CD4+ and CD8+ T cells)
(Fig. 2). Although levels seemed to converge by 28 days,
HLA-DR expression was consistently and persistently higher
in SIVmac infected than SHIV infected macaques, and signifi-
cantly higher in chronic infection (Fig. 2). These data demons-
trate distinct immunologic sequela apparent in very early
infection that may distinguish immune responses in macaques
that sustain plasma viremia from those that eventually control
viral replication.
Correlation of early T cell proliferation and peak SIV
viremia
Recent studies suggest that the kinetics of proliferating T and B
cells may be related to the dynamics of early SIV replication in
progressing and nonprogressing hosts [17,18]. Here we compared
T-cell proliferation using Ki-67 as a marker of cycling lymphocytes
in acute SHIVsf162P3 and SIVmac251-infection. The represen-
tative gating strategy for Ki67+ T-cell is shown in Figure 3A). Peak
T cell proliferation occurred by 21 days postinfection in
SIVmac251 infected macaques, and CD4+ T cell proliferation
increased significantly from 14 to 21 days (from 3.427% to
19.37%) (Fig. 3). At 21 days of infection, the level of proliferating
CD3+T cells, CD4+T cells and CD8+T cells in SIVmac251
infected macaques were all significantly higher than those infected
with SHIV162p3 (from 16.56% to 56.1%, 5.096% to 37%,
31.12% to 66.58% (p,0.001; p,0.05 and p,0.01 respectively),
However T-cell proliferation decreased thereafter, and by day 28,
values were indistinguishable between cohorts. However, T cell
proliferation continued to diminish in SHIV162p3-infected
animals to baseline levels, but stabilized in SIVmac251 infected
animals at levels significantly higher than those of baseline, or
SHIV-infected animals, indicating sustained T cell proliferation/
activation in SIVmac infection.
Comparison of early cytokine/chemokine responses in
acute SHIV and SIV infection
As described above and illustrated in Figs. 2–3, pathogenic
SIVmac251 infection results in marked immune activation and
cell proliferation that is likely predictive of disease progression.
Since lymphokines play a key role in immune regulation, this
activation/proliferation should be accompanied by burst of
cytokine/chemokine release upon SIV infection. To further
correlate early host immune responses with immune activation
and viremia, a comprehensive quantitative analysis of lymphokines
produced in response to SHIVsf162P3 and SIVmac251-infection
in macaques was performed. As shown in Fig. 4A, pro-
inflammatory cytokines including IL-1b and TNF-a were
markedly elevated and sustained in plasma of SIV infected
macaques thorough 21 days of infection. In contrast, levels of these
cytokines were markedly lower in macaques infected with
SHIV162p3 at this time point (P,0.05). In HIV/SIV infection,
an imbalance of Th-1 Th2 cytokines has been suggested to occur.
However, we found that in both SHIV162p3 and SIVmac251
infected macaques, both Th-1 (IL-2, IFN-c) and Th-2 (IL-4, IL-5,
IL-6, IL-10, and IL-13) type cytokines were markedly elevated
after infection. Further, levels of all cytokines were significantly
higher in macaques infected with SIVmac than in SHIV162p3 at
day 21 (P,0.05) (Fig. 4B, C). Other cytokines such as IL-7, IL-9
and IL-17 were markedly higher in SIVmac251-infected ma-
caques than in SHIVsf162P3 infected animals (data not shown).
Combined, these data indicate that pathogenic SIVmac251
infection results in much stronger early immune responses
including increased cytokine secretion, T cell activation, and
proliferation, and this early response may correlate with a poor
prognosis.
In addition to cytokines, levels of several chemokines including
MIP-1a, MIP-1b, MCP-1, RANTES, IL-8 and IP-10 were also
elevated in plasma of animals infected with either virus (Fig. 5).
Both infections resulted in increased levels of chemokines in
plasma, but only IP-10 showed significant differences between
SHIVsf162P3 and SIVmac251 inoculated macaques (Fig. 5). IP-
10 expression was significantly up-regulated in SIVmac251
infection at day 21, compared with SHIVsf162P3 infection
(P,0.05). As an IFN-inducible protein, increased IP-10 expression
further indicates that SIVmac251 inoculation results in immune
activation and a brief, yet marked cytokine/chemokine ‘‘storm’’
that is not paralleled in intensity by less pathogenic infections,
despite the similar high primary viremia in both cohorts.
These results demonstrate pathogenic SIV infection results in a
marked cytokine/chemokine inflammatory response during acute
infection, which likely promotes ongoing viral replication, and may
mediate immunopathology by favoring both direct and bystander
immune activation, T cell proliferation, and may predict disease
progression. Interestingly however, lymphokine levels essentially
converge in macaques infected with either virus by day 42,
regardless of the inoculum/infection. Elevated plasma levels of
cytokines in SIVmac251 infected animals provide additional
evidence that immune activation is associated with pathogenic
infection. Further, and similar to SIV infection of natural or non-
progressing hosts [7,8,19] SHIV162p3 infected macaques had a
Figure 2. Dynamics of activated T cells in blood as determined by HLA-DR expression on T cell subsets. A) Representative gating
strategy showing HLA-DR expression on CD3+ T cells prior to infection and 21 days after infection. B) Mean percentages of HLA-DR expression on
total T cells (CD3+), and on CD4+ and CD8+ T cell subsets in SHIVsf162p3 (filled circles) and SIVmac251-infected (open squares) RMs in early and
chronic (3 months) infection. Means6SEM are shown. Asterisks indicate significant differences (P,0.05) between groups.
doi:10.1371/journal.pone.0017965.g002
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chemokines hardly changed from baseline levels throughout
primary infection, despite high viremia at 14–28 days of infection.
Note that IL-1, IL-6, IL-10, IL-12, TNF-a and IFN-c, levels in
SIVmac251-infected animals were significantly higher than
SHIV162p3 infected macaques at 21 days postinfection
(P,0.05) which was peak viremia for SHIV162p3-infected
macaques. In summary, pathogenic SIVmac251 infection results
in significantly higher levels of essentially all major classes of
cytokines as well as several chemokines compared to SHIVsf162P3
infection. Although a definitive cause and effect relationship was
beyond the scope of this study, higher levels of lymphokines in
plasma clearly correlate with increased cell activation and T cell
proliferation, which may contribute to the sustained viremia in
SIVmac251 infected cohorts.
Equal loss of peripheral central memory CD4+ T cells in
early infection
As shown above and in previous studies, macaques intravagi-
nally infected with SHIV162p3 generally do not progress to AIDS,
and survival has been associated with preservation or restoration
of central memory CD4+ T lymphocytes. Thus, we compared
changes in blood of central memory CD4+ T cells in early
SHIV162p3 and SIVmac251 inoculation. The representative
gating strategy for central memory CD4+ T-cells is shown in
Fig. 6A). Remarkably, and despite significant differences in
immune activation and lymphocike production, percentages of
peripheral CD4+ central memory T cells were markedly and
reduced in both viruses in early infection, with no apparent
differences detected before 21 days p.i between groups (Fig. 6B).
However, percentages of central memory CD4+ T cells then
increased in SHIV162P3-infected macaques at day 28 postinfec-
tion, to levels higher than SIVmac251-infected animals (from
33.7% to 20.23%, P,0.05). In chronic phase (3 month p.i.), the
frequency of circulating central memory CD4+ T-cells in
SIVmac251-infected animals increased to some extent, and there
were no significant differences compared with SHIV162p3
infected animals, although levels remained higher than in
SIVmac251 infected macaques. Combined, these data suggest
that in early infection, viral replication and target cell infection and
destruction are similar in the two infections, yet eventually,
viremia is controlled and central memory CD4+ T cells begin to
recover in SHIV-infected macaques.
Discussion
We previously reported that intravaginal inoculation with
SHIV162p3 results in transient viremia followed by undetectable
viral loads in most macaques, yet many of these animals showed
remarkable protection to subsequent intravenous SIVmac251
challenge. Although the prior study clearly showed prior infection
confers resistance to superinfection/viremia with a more patho-
genic virus, the mechanisms of this protection remain unclear.
The current study demonstrated that intravaginal inoculation of
naı ¨ve RMs with either SHIVsf162P3 or pathogenic SIVmac251
results in early active viral replication, T-cell activation, prolifer-
ation, and a burst of cytokine/chemokine release, but SIVmac251
infection results in significantly higher levels of activation and
lymphokine production very early in infection compared to
SHIVsf162P3 infection. Since the level of central memory
CD4+ T cell loss was similar at these timepoints, this suggest
that the early immune response to HIV-1 infection is likely to be
an important factor in determining the clinical course of disease.
Further, it has been proposed that very early impairment of
immune responses may contribute to subsequent viral escape
mutations [20]. Combined, these data all suggest very early
divergence in immune responses to SIV infection could be
predictive of disease outcome and vaccine efficiency.
Resistance to progressive or pathogenic infection in SIV/SHIV
infected macaques may be associated with an effective host
immune response, as some individuals maintain high viremia and
progress to AIDS, whereas most eventually clear infection and are
resistant to subsequent challenge. However, unlike macaques,
primate species that naturally resist disease progression when
infected with SIV (African Green monkeys, Sooty mangabeys, etc)
still harbor high viremia, despite lack of progression to AIDS.
Although these animals have evolutionary adaptations that are
likely responsible for lack of disease progression, infection of
natural hosts is also characterized by limited activation, prolifer-
ation, and preserved central memory T cells [7,8,19]. Here we
compared early host responses within identical cohorts of rhesus
macaques following intravaginal SHIVsf162p3 and SIVmac251
inoculation. These data show the early dynamics of T-cell
activation, proliferation and cytokine levels in plasma positively
correlated with virus replication. Immune responses for almost all
parameters tested were significantly higher in SIVmac251 than
SHIVsf162P3-infected macaques. Of note, host responses gradu-
ally converged to similar levels in both cohorts by 28 days of
infection, which suggests early host responses such as levels of T-
cell activation and proliferation are key to disease progression, and
early suppression may be key to viral containment, a theory
previously proposed for non-progressing host species.
Higher immune activation and proliferation after SIV infection
is purportedly associated with higher levels of T cell apoptosis, and
central memory CD4+ T-cells are considered preferential targets
for ‘‘bystander’’ activation [21,22]. However, the level of central
memory CD4+ T cell destruction was essentially identical in early
infection, indicating that target cell availability of ability to infect/
destroy these cells was not likely a factor in early infection or the
outcome.
Importantly, the early cytokine responses were largely domi-
nated by the induction of proinflammatory cytokines, which may
amplify the immunopathology during early HIV infection [11,23].
In pathogenic SIVmac251 infection, marked increases in essen-
tially all cytokines/chemokines tested were detected in plasma
through 56 days postinfection, and significantly elevated levels of
IL-1b, IL-6, IL-10 and TNF-a, were detected at day 21 infection
in SIVmac251-infected macaques compared with SHIV162P3
infected macaques. Elevated levels of several cytokines/chemo-
kines in plasma are consistent with marked immune activation (a
cytokine ‘‘storm’’) which could result in increased viral infection
and amplification in multiple cells and tissue sites. Further, this
elevated cytokine milieu could favor continued or sustained
immune cell activation, resulting in continued cell turnover, and
destruction of viral target cells in SIV infection. Thus, early,
constrained immune activation and proliferation might contribute to
reduced lymphocyte destruction, preservation of memory T cells,
and lower viral amplification in tissues, at least until effective
Figure 3. T-cell proliferation during acute SIV infection. A) Representative gating strategy showing Ki-67 expression on CD3+ T cells prior to
and 21 days after infection. B) Longitudinal analysis of early T-cell proliferation in blood from SHIVsf162p3 (filled circles) and SIVmac251-infected RMs
(open squares). Means6SEM are shown. Significant differences (P,0.05) between groups are indicated by asterisks.
doi:10.1371/journal.pone.0017965.g003
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infections.
In summary, marked differences in early host responses
including T-cell activation and proliferation, and cytokine/
chemokine responses were detected between macaques intravag-
inally infected with the minimally pathogenic SHIVsf162P3 and
highly pathogenic SIVmac251, suggesting that early immune
activation and proliferation are key factors in AIDS pathogenesis,
and associated with disease outcome. Classically, investigators
have sought enhanced immune responses for correlates of
protection, and vaccine candidates are usually selected and
advanced based on their ability to induce more potent immune
responses to viral antigens. In contrast, in non-progressing host
species, it has been proposed that suppressed immune response are
Figure 4. Levels of proinflammatory cytokines (A), Th1 cytokines (B), and Th2 cytokines (C) in plasma of SHIVsf162p3 (filled circles)
and SIVmac251-infected RMs (open squares). Means6SEM are shown. *Asterisks indicate significant differences between groups (P,0.05).
doi:10.1371/journal.pone.0017965.g004
Figure 5. Changes in chemokine levels in plasma in acute SHIVsf162p3 (filled circles) and SIVmac251-infected RMs (open squares).
Means6SEM are shown. *Asterisks indicate significant differences between groups (P,0.05).
doi:10.1371/journal.pone.0017965.g005
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within the same species of susceptible macaques, dampened
immune responses to a virus that initially proliferates well within
the host, may be associated with long term control and potential
clearance of the virus. If so, perhaps vaccine strategies aimed at
inducing temporary ‘‘tolerance’’, rather than ‘‘stimulatory’’
responses, may preserve key immunoregulatory cells and give
the host time to mount effective immune responses. Regardless,
these findings may hold promise for design of novel preventive and
therapeutic strategies to combat HIV infection.
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